AN2 Therapeutics (ANTX) Receivables - Net (2023 - 2024)

AN2 Therapeutics (ANTX) reported Receivables - Net of $100000.0 for Q1 2024, down 83.33% quarter-over-quarter from $600000.0 in Q4 2023.

AN2 Therapeutics (ANTX) Receivables - Net (2023 - 2024) Analysis & Trends

AN2 Therapeutics (ANTX) has 2 years of Receivables - Net data on file, last reported at $100000.0 in Q1 2024.

Receivables - Net for Q1 2024 came in at $100000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $100000.0 (changed N/A YoY), and the FY2023 annual result was $600000.0, changed N/A from the prior year.
Receivables - Net declined to $100000.0 in Q1 2024 per ANTX's latest filing, from $600000.0 in the prior quarter.
Over five years, Receivables - Net peaked at $600000.0 in Q4 2023 and troughed at $100000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	AN2 Therapeutics	161.95 Mn	161.95 Mn	-

Download Data